1. Hall, Ashley, Moore, Anni K, Hernandez, Dena G, Bubb, Vivien J, Quinn, John P. 2020. A SINE-VNTR-Alu in the LRIG2 Promoter Is Associated with Gene Expression at the Locus. In International journal of molecular sciences, 21, . doi:10.3390/ijms21228486. https://pubmed.ncbi.nlm.nih.gov/33187279/
2. Hall, Ashley, Middlehurst, Ben, Cadogan, Max A M, Bubb, Vivien J, Quinn, John P. 2024. A SINE-VNTR-Alu at the LRIG2 locus is associated with proximal and distal gene expression in CRISPR and population models. In Scientific reports, 14, 792. doi:10.1038/s41598-023-50307-w. https://pubmed.ncbi.nlm.nih.gov/38191889/
3. Li, Zhi-Qiang, Liao, Wei-Jie, Sun, Bo-Lin, Liu, Zhi-Li, Liu, Jia-Ming. 2022. LRIG2 regulates cell proliferation, migration and apoptosis of osteosarcoma. In BMC cancer, 22, 1029. doi:10.1186/s12885-022-10123-3. https://pubmed.ncbi.nlm.nih.gov/36183058/
4. Dong, Minhai, Xiao, Qungen, Hu, Jinyang, Guo, Dongsheng, Wang, Baofeng. 2020. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. In Cancer gene therapy, 27, 878-897. doi:10.1038/s41417-020-0163-1. https://pubmed.ncbi.nlm.nih.gov/31988476/
5. Hoesl, Christine, Fröhlich, Thomas, Hundt, Jennifer E, Schneider, Marlon R, Dahlhoff, Maik. 2019. The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis. In Molecular oncology, 13, 2476-2492. doi:10.1002/1878-0261.12579. https://pubmed.ncbi.nlm.nih.gov/31580518/
6. Roberts, Neil A, Hilton, Emma N, Lopes, Filipa M, Newman, William G, Woolf, Adrian S. 2019. Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder. In Kidney international, 95, 1138-1152. doi:10.1016/j.kint.2018.11.040. https://pubmed.ncbi.nlm.nih.gov/30885509/
7. Lindquist, David, Kvarnbrink, Samuel, Henriksson, Roger, Hedman, Håkan. 2014. LRIG and cancer prognosis. In Acta oncologica (Stockholm, Sweden), 53, 1135-42. doi:10.3109/0284186X.2014.953258. https://pubmed.ncbi.nlm.nih.gov/25180912/
8. Rondahl, Veronica, Holmlund, Camilla, Karlsson, Terese, Henriksson, Roger, Hedman, Håkan. 2013. Lrig2-deficient mice are protected against PDGFB-induced glioma. In PloS one, 8, e73635. doi:10.1371/journal.pone.0073635. https://pubmed.ncbi.nlm.nih.gov/24023893/
9. Suh, Dae-Shik, Park, Si Eun, Jin, Hanyong, Lee, Kangseok, Bae, Jeehyeon. 2018. LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle. In Oncogenesis, 7, 3. doi:10.1038/s41389-017-0019-1. https://pubmed.ncbi.nlm.nih.gov/29358688/
10. Xiao, Qungen, Dong, Minhai, Cheng, Fangling, Lei, Ting, Guo, Dongsheng. 2018. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling. In International journal of oncology, 53, 1069-1082. doi:10.3892/ijo.2018.4482. https://pubmed.ncbi.nlm.nih.gov/30015847/
智鼠故事 
